What To Expect From BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings [Yahoo! Finance]
BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer’s Dementia
BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024
Will BioXcel Therapeutics, Inc. (BTAI) Report Negative Q3 Earnings? What You Should Know [Yahoo! Finance]
BioXcel Therapeutics to Present at ThinkEquity Conference